Trial Profile

A phase III study of tarenflurbil spray for the treatment of skin diseases.

Status: Planning

Phase of Trial: Phase III

Latest Information Update: 22 Jan 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tarenflurbil (Primary)
Indications Skin disorders
Focus Adverse reactions; Proof of concept; Therapeutic Use

Most Recent Events

22 Jan 2016 New trial record
12 Dec 2008 According to a MIKA Pharma GmbH media release, phase III proof-of-concept trial will be finance by GALEN pharma.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com